Teva Pharmaceutical Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	1,410	-1,639	-559	-2,446	417
Depreciation & Amortization	1,002	1,059	1,153	1,308	1,330
Loss (Gain) From Sale of Assets	-	-22	-41	10	-
Asset Writedown & Restructuring Costs	1,028	2,555	1,078	2,447	594
Loss (Gain) From Sale of Investments	-	-	-	-	104
Stock-Based Compensation	157	123	121	124	119
Other Operating Activities	-582	-394	-312	-1,208	-65
Change in Accounts Receivable	-173	245	12	334	-574
Change in Inventory	152	166	-147	-163	380
Change in Accounts Payable	-15	258	1,588	2,012	764
Change in Other Net Operating Assets	-1,330	-1,104	-1,525	-828	-2,271
Operating Cash Flow	1,649	1,247	1,368	1,590	798
Operating Cash Flow Growth	32.24%	-8.85%	-13.96%	99.25%	-34.38%
Capital Expenditures	-501	-498	-526	-548	-562
Cash Acquisitions	-	-15	-	-7	-
Divestitures	34	43	68	68	311
Investment in Securities	-15	-31	-46	3	125
Other Investing Activities	5	2	-5	-	1
Investing Cash Flow	737	792	968	656	1,523
Short-Term Debt Issued	-	-	700	-	700
Long-Term Debt Issued	2,298	-	2,451	-	4,974
Total Debt Issued	2,298	-	3,151	-	5,674
Short-Term Debt Repaid	-	-	-700	-	-700
Long-Term Debt Repaid	-4,112	-1,641	-4,152	-1,369	-7,140
Total Debt Repaid	-4,112	-1,641	-4,852	-1,369	-7,840
Net Debt Issued (Repaid)	-1,814	-1,641	-1,701	-1,369	-2,166
Other Financing Activities	-337	-150	-212	-118	-6
Financing Cash Flow	-2,151	-1,791	-1,913	-1,487	-2,172
Foreign Exchange Rate Adjustments	21	-174	-30	-123	-128
Net Cash Flow	256	74	393	636	21
Free Cash Flow	1,148	749	842	1,042	236
Free Cash Flow Growth	53.27%	-11.04%	-19.19%	341.52%	-63.01%
Free Cash Flow Margin	6.65%	4.53%	5.31%	6.98%	1.49%
Free Cash Flow Per Share	0.99	0.66	0.75	0.94	0.21
Cash Interest Paid	950	1,004	1,078	948	913
Cash Income Tax Paid	558	471	298	543	495
Levered Free Cash Flow	2,032	2,623	3,298	2,900	2,307
Unlevered Free Cash Flow	2,604	3,249	3,941	3,481	2,863
Change in Working Capital	-1,366	-435	-72	1,355	-1,701

Updated Jan 28, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q